A multi-metabolite signature robustly predicts long-term mortality in the PREDIMED trial and several US cohorts.
Authors | |
Keywords | |
Abstract | Metabolome-based biomarkers contribute to identify mechanisms of disease and to a better understanding of overall mortality. In a long-term follow-up subsample (n = 1878) of the PREDIMED trial, among 337 candidate baseline plasma metabolites repeatedly assessed at baseline and after 1 year, 38 plasma metabolites were identified as predictors of all-cause mortality. Gamma-amino-butyric acid (GABA), homoarginine, serine, creatine, 1-methylnicotinamide and a set of sphingomyelins, plasmalogens, phosphatidylethanolamines and cholesterol esters were inversely associated with all-cause mortality, whereas plasma dimethylguanidino valeric acid (DMGV), choline, short and long-chain acylcarnitines, 4-acetamidobutanoate, pseudouridine, 7-methylguanine, N6-acetyllysine, phenylacetylglutamine and creatinine were associated with higher mortality. The multi-metabolite signature created as a linear combination of these selected metabolites showed a strong association with all-cause mortality using plasma samples collected in PREDIMED also at 1-year follow-up. This association was subsequently confirmed in 4 independent American cohorts, validating the signature as a consistent predictor of all-cause mortality across diverse populations. |
Year of Publication | 2025
|
Journal | Metabolism: clinical and experimental
|
Pages | 156195
|
Date Published | 03/2025
|
ISSN | 1532-8600
|
DOI | 10.1016/j.metabol.2025.156195
|
PubMed ID | 40107652
|
Links |